We are live on ! Find out more
AUPH icon

Aurinia Pharmaceuticals
AUPH

115 hedge funds and large institutions have $992M invested in Aurinia Pharmaceuticals in 2019 Q4 according to their latest regulatory filings, with 52 funds opening new positions, 28 increasing their positions, 19 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

629% more capital invested

Capital invested by funds: $136M → $992M (+$856M)

550% more first-time investments, than exits

New positions opened: 52 | Existing positions closed: 8

127% more call options, than puts

Call options by funds: $89.1M | Put options by funds: $39.3M

60% more funds holding

Funds holding: 72 → 115 (+43)

47% more repeat investments, than reductions

Existing positions increased: 28 | Existing positions reduced: 19

17.96% more ownership

Funds ownership: 27.74% → 45.7% (+18%)

Holders
115
Holders Change
+43
Holders Change %
+59.72%
% of All Funds
2.27%
Holding in Top 10
6
Holding in Top 10 Change
+6
Holding in Top 10 Change %
% of All Funds
0.12%
New
52
Increased
28
Reduced
19
Closed
8
Calls
$89.1M
Puts
$39.3M
Net Calls
+$49.8M
Net Calls Change
+$49.3M

Top Buyers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
+$63.6M
2
CCM
Consonance Capital Management
New York
+$37.4M
3
HM
HealthCor Management
New York
+$36.7M
4
Point72 Asset Management
Point72 Asset Management
Connecticut
+$32.9M
5
BBA
Baker Bros. Advisors
New York
+$15.7M

Top Sellers

Rank Fund Capital Flow
1
PC
Polar Capital
United Kingdom
-$17.7M
2
O
OrbiMed
New York
-$10.9M
3
Goldman Sachs
Goldman Sachs
New York
-$9.5M
4
Ameriprise
Ameriprise
Minnesota
-$1.96M
5
D.E. Shaw & Co
D.E. Shaw & Co
New York
-$1.79M
Name Holding Trade Value Shares
Change 		Change in
Stake
ARTA
51
A.R.T. Advisors
New York
$1.23M +$450K +48,800 +410%
UBS AM
52
UBS AM
Illinois
$1.12M +$357K +38,800 +236%
NFG
53
Norris Financial Group
South Carolina
$1.1M +$502K +54,528 New
Stifel Financial
54
Stifel Financial
Missouri
$1M +$60.5K +6,573 +15%
CS
55
Credit Suisse
Switzerland
$1M +$245K +26,552 +116%
Vanguard Group
56
Vanguard Group
Pennsylvania
$971K +$174K +18,929 +65%
FAM
57
Fred Alger Management
New York
$952K +$433K +47,000 New
Verition Fund Management
58
Verition Fund Management
Connecticut
$933K +$424K +46,054 New
MIM
59
Monashee Investment Management
Massachusetts
$912K +$415K +45,000 New
KCM
60
Kingdon Capital Management
New York
$885K +$402K +43,669 New
ERSOT
61
Employees Retirement System of Texas
Texas
$733K +$333K +36,178 New
Toronto Dominion Bank
62
Toronto Dominion Bank
Ontario, Canada
$658K +$178K +19,285 +146%
Squarepoint
63
Squarepoint
New York
$589K +$268K +29,095 New
RJA
64
Raymond James & Associates
Florida
$576K +$262K +28,445 New
Jane Street
65
Jane Street
New York
$527K +$240K +26,024 New
CM
66
Caption Management
Oklahoma
$506K +$230K +25,000 New
Voloridge Investment Management
67
Voloridge Investment Management
Florida
$432K +$196K +21,322 New
ProShare Advisors
68
ProShare Advisors
Maryland
$413K -$41K -4,453 -18%
VF
69
Virtu Financial
New York
$412K -$22.7K -2,462 -11%
Deutsche Bank
70
Deutsche Bank
Germany
$402K +$183K +19,857 New
QSS
71
Quantitative Systematic Strategies
Florida
$370K +$168K +18,264 New
HWM
72
HighMark Wealth Management
Minnesota
$350K +$160K +17,316 New
HT
73
HAP Trading
New York
$322K +$146K +15,870 New
Citigroup
74
Citigroup
New York
$257K +$77.8K +8,447 +200%
TCWM
75
Total Clarity Wealth Management
Illinois
$234K +$107K +11,562 New
1 2
3
4 5

AUPH Hedge Fund Activity: Q4 2019 in Review

115 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in Aurinia Pharmaceuticals (AUPH) for Q4 2019, worth a combined $992M — up 629% from $136M a quarter earlier.

Buyers outnumbered sellers: 52 funds opened new AUPH positions and 8 closed out — a net gain of 44 holders — while 28 added to existing stakes and 19 trimmed.

The largest buyer was Fidelity Investments, adding an estimated $63.6M. The largest seller was Polar Capital, exiting entirely with an estimated $17.7M sold.

  • 115 institutional investors held Aurinia Pharmaceuticals (AUPH) as of Q4 2019, up from 72 in Q3 2019.
  • Funds reported $992M of Aurinia Pharmaceuticals stock for Q4 2019, up 629% quarter-over-quarter.
  • 52 funds opened new Aurinia Pharmaceuticals positions in Q4 2019 and 8 closed out, a net change of +44 holders.
  • The largest Aurinia Pharmaceuticals buyer in Q4 2019 was Fidelity Investments, an estimated $63.6M added.
  • The largest Aurinia Pharmaceuticals seller in Q4 2019 was Polar Capital, an estimated $17.7M sold.

Based on aggregated 13F filings for Q4 2019.